Objectives To evaluate the very long-term safety and effectiveness of drug-eluting stents (DES) compared to bare-metal stents (BMS) for patients with large coronary vessels. Methods From April 2004 to October 2006, 2407 consecutive patients undergoing de novo lesion percutaneous coronary intervention with reference vessel diameter greater than or equal to 3.5 mm at Fu Wai Hospital in Beijing, China, were prospectively enrolled into this study. We obtained 9-year clinical outcomes including death, myocardial infarction (MI), thrombosis, target lesion revascularization (TLR), target vessel revascularization (TVR), and major adverse cardiac events (MACE, the composite of death, MI, and TVR). We performed Cox's proportional-hazards models to assess relative risks of all the outcome measures after propensity match. Results After propensity scoring, 514 DES-treated patients were matched to 514 BMS-treated patients. The patients treated with BMS were associated with higher risk of TLR (HR: 2.55, 95%CI: 1.520-4.277, P = 0.0004) and TVR (HR: 1.889, 95%CI: 1.185-3.011, P = 0.0075), but the rates of death/MI and MACE were not statistically different. All Academic Research Consortium definition stent thrombosis at 9-year were comparable in the two groups. Conclusions During long-term follow-up through nine years, use of DES in patients with large coronary arteries was still associated with significant reductions in the risks of TLR and TVR.
Introduction


Compared with bare-metal stents (BMS), randomized trials have demonstrated that drug-eluting stents (DES) can reduce the risk of target vessel revascularization (TVR). [1] This benefit is particularly large for patients with smaller coronary arteries, but smaller in larger vessels where the risk of restenosis is lower. [2] Furthermore, subgroup analyses of BASKET trial showed that there was a higher rate of late stent thrombosis-related events in patients with large coronary arteries treated with DES than BMS. [3] It is unknown whether DES is superior to BMS for larger coronary arteries in the setting of routine clinical practice. This study sought to evaluate the very long-term safety and effective-ness of DES compared to BMS for patients with large coronary vessels.
Methods
Study population
From April 2004 to October 2006, 2407 consecutive patients undergoing de novo lesion percutaneous coronary intervention (PCI) with reference vessel diameter greater than or equal to 3.5 mm by visual estimation on angiogram by the operator at Fu Wai Hospital (Beijing, China), were prospectively enrolled into this study. All enrolled patients were divided into DES group (n = 1620) and BMS group (n = 787).
We excluded the patients with acute ST-elevation myocardial infarction treated with primary PCI from analysis, as the patients who received both DES and BMS. The study complied with the Declaration of Helsinki and was approved by the Ethics Committee of Fu Wai Hospital.
Procedure and periprocedural practices
Decisions regarding for interventional strategy and in-strumentation used were made by the interventional cardiologists. Administration of periprocedural antiplatelet and antithrombotic medications was based on operator's discretion and current guidelines. Lifelong aspirin (100 mg/d) was prescribed to all patients. One year of clopidogrel (75 mg/d) was recommended to all patients treated with DES. At least three months of clorpidogrel (75 mg/d) was recommended to the patients treated with BMS.
Follow-up data collection and main outcome measures
Clinical follow-up were performed at 3, 12 and 24 months and 9 years through an outpatient clinic visit or by telephone interview. We compared the combination of all-cause mortality and myocardial infarction (MI), target lesion revascularization (TLR), TVR, and major adverse cardiovascular events (MACE, the composite of mortality, MI, and TVR) between the two groups at 9-year point, as well as the risk difference for stent thrombosis (definite, probable, possible thrombosis, early thrombosis, late thrombosis, very late thrombosis). All end points were defined according to Academic Research Consortium (ARC) definitions. [4] 
Statistical analysis
Because patients in our study were not randomized to receive either DES or BMS, we utilized propensity-score matching of subjects to adjust for differences of baseline characteristics in the two groups. [5] We selected all available variables that might be of potential relevance. Thirty variables were employed in propensity-score matching, including gender, age, diabetes mellitus, hypertension, hyperlipidemia, prior MI, prior PCI, prior coronary artery bypass grafting (CABG), family history of coronary artery disease (CAD), prior cerebral vascular disease, prior peripheral vascular disease, smoking history, angina pectoris, left ventricular ejection fraction, multiple vessel disease, number of target lesions, number of stents, target lesion location, reference vessel diameter by visual estimate, lesion length by visual estimate, pre-and post-procedural percentage diameter stenosis by visual estimate, ACC/AHA lesion type, total occlusion, ostial lesion, bifurcation, total stent length, calcification, post-dilatation, and intravascular ultrasound usage. A 1: 1 matched analysis was performed without replacement on the basis of the estimated propensity score of each patient in the study. If the difference of the estimated propensity score between DES and BMS group is < 0.01, then these two patients were eligible for matching.
Continuous variables were reported as mean ± SD and compared through the use of the Student unpaired t test on data before propensity match or of Student paired t test on that after propensity match. Categorical variables were presented as counts and percentages, and were compared using the  2 test. In the study cohort, the reduction in the risk of all the outcome measures at 9 years was compared with Cox's proportional-hazards models. The results are reported as hazard ratio (HR) with 95% confidence interval (CI). Cumulative incidences concerning endpoints of the cohort after propensity match were estimated by the Kaplan-Meier method and compared by use of the log-rank test. All statistical tests were two sided, and value of P < 0.05 was considered to indicate statistical significance. All analyses were performed with SAS 9.3 system (SAS Institute, Cary, NC, USA). clinical profiles including older age as well as greater incidences of prior MI, unstable angina, and total occlusion lesion, but less of hyperlipidemia, prior PCI, multi-target vessel, left anterior descending artery lesions, bifurcation and ostial lesions, lesion and stent length, and post-dilatation. After propensity match, 514 DES-treated patients were matched to 514 BMS-treated patients, and the baseline profiles in the two groups became comparable (Table 3 and Table 4 ). The logistic model which was used to calculate the propensity score presented good predictive value (C statistic = 0.818).
Results
Patient
Clinical outcomes after propensity match
The median follow-up for surviving patients was about nine years, and the follow-up period was similar for two groups (2795.9 ± 1181.9 vs. 2890.9 ± 1309.3 days, P = 0.2146). Cumulative incidences of the various adverse events in the two groups after propensity match were listed in Table 5 . At 1-year and 2-year follow-up, patients with DES had significantly lower rates of TLR (1.8% vs. 6.4%, P = 0.0001 and 2.3% vs. 8.0%, P < 0.0001), TVR (3.3% vs. 7.8%, P = 0.016 and 4.3% vs. 9.7%, P = 0.0006) and MACE (4.5% vs. 9.3%, P = 0.0016 and 5.6% vs. 11.5%, P = 0.0007). At 9 years, the rates of TLR and TVR remained significantly lower in patients with DES (4.1% vs. 10.7%, P = 0.0001 and 5.6% vs. 11.3%, P = 0.0011, respectively). While concerning the rate of MACE at 9 years, the results showed a non-significant trend towards superiority of DES group (13.0% vs. 17.3%, P = 0.0574). Kaplan-Meier curves ( Figure 1 ) showed no differences in 9-year cumulative incidences of mortality, MI and definite/probable thrombosis, but DES implantation was associated with a lower risk of TLR (5.0% vs. 12.0%, P < 0.0001), TVR (6.0% vs. 12.0%, P = 0.0012) and MACE (15.0% vs. 19.0%, P = 0.0365). Table 6 shows the comparisons of adjusted 9-year cumulative incidences of the various adverse events evaluated with Cox's proportional-hazards models in the two groups after propensity match. The patients treated with BMS were associated with higher risk of TLR (HR: 2.55, 95%CI: 1.520-4.277, P = 0.0004) and TVR (HR: 1.889, 95%CI: 1.185-3.011, P = 0.0075). However, death/MI rates, stent thrombosis rates and MACE were not significantly different between the groups.
The cumulative incidences of thrombosis at 9 years were showed in Table 7 . All the specifications of thrombosis rates, according to ARC definitions, were comparable between DES and BMS.
Discussion
The major findings in the current study were that the use of DES in large coronary arteries was associated with significantly lower rates of TLR and TVR but with similar death/MI or stent thrombosis compared with BMS during a 9-year clinical follow-up. This finding demonstrated that the important advantage of a lower restenosis rate with DES over BMS in large vessels existed till very long term.
Our findings were consistent with those of previous trials. An analysis of TAXUS IV trial showed that patients with DES had significantly lower revascularization rates than BMS (HR: 0.48, 95% CI: 0.25-0.92) in the large vessel (> 3.0 mm) subgroup. [6] The BASKET-PROVE trial, which included vessels > 3.0 mm patients, also showed that the rate of TVR was significantly reduced among patients receiving DES, as compared with BMS during a 2-year follow-up. [7] Recently, a meta-analysis of randomized controlled trials included 4399 patients and demonstrated that DES is superior to BMS in terms of clinical events in large coronary arteries. [8] In our current study, the rates of TLR and TVR showed significantly lower in patients with DES (4.1% vs. 10.7%, P = 0.0001 and 5.6% vs. 11.3%, P = 0.0011, respectively) compared with BMS for large coronary arteries (≥ 3.5 mm) during a 9-year clinical follow-up.
However, other previous studies showed that there were no significantly different about clinical outcome between DES and BMS in large coronary artery lesions.
[913] They thought that, given a similar degree of neointimal hyperplasia around a stent of any diameter, a larger reference vessel size would be associated with a relatively lower rate of restenosis and events. [10, 14] Nevertheless, it is also important to note that in-stent restenosis depended on several clinical factors, such as diabetic status, lesion complexity and stent length. A propensity-score-matched study showed that the rates of TVR were comparable between the DES group and the BMS group in patients with lower risk for restenosis (no diabetes, large vessel and short lesions), [15] while DES was associated with significant reduction of TVR in patients with high risk of restenosis. A previous study in our center, [16] which included non-diabetic patients with simple de novo lesions (stent diameter > 3.0 mm and stent length < 18 mm), showed that there was no significant difference in the risk of MACEs between BMS and DES. On the other hand, the SIRIUS trial, [17] which included 1058 patients with complex coronary lesions, revealed that the use of sirolimus-eluting stent had a reduction in the rates of restenosis and associated clinical events compared to BMS in both small-vessel (< 2.75 mm) and large-vessel (> 2.75 mm) subgroups. These studies indicated that BMS might be equivalent to DES only in simple lesions at low risk of restenosis, such as nondiabetic, diameter > 3 mm and lesion length < 15 mm. In this study, we enrolled consecutive patients undergoing PCI with larger coronary arteries in the setting of routine clinical practice, both groups including comparable complex lesions, such as diabetes and long lesion (> 30 mm). This might explain why the results of this study disagree with those of studies with regard to no additional benefit of DES implantation compared with BMS in larger coronary arteries.
Moreover, the great baseline differences of demographic and procedural characteristics between groups might have influence on angiographic and clinical outcomes. The analysis from National Heart, Lung and Blood Institute (NHLBI)-sponsored dynamic registry showed that in large coronary arteries, defined by a vessel diameter greater than or equal to 3.5 mm, DES provided no additional effectiveness over BMS in terms of TVR. [13] In this NHLBI dynamic registry, DES patients were more likely to have history of renal disease, hypertension, hypercholesterolemia and history of prior PCI compared to BMS; the mean reference vessel size of treated lesions was smaller (3.6 vs. 3.7 mm, P < 0.01) and mean lesion length was longer (16.7 vs. 13.6 mm, P < 0.01) in DES patients, which might be the part of reason why this study failed to show superiority of DES in efficacy and safety. Our study utilized propensity-score matching of subjects to adjust for differences of baseline characteristics in the two groups. After propensity match, the baseline profiles in the two groups became almost identical.
The effect of the use of DES on long-term mortality has not previously been established. [18] Our study showed no difference in mortality between patients with DES and those with BMS during a 9-year period, either for the combined end point of death or myocardial infarction.
There were still several safety concerns with DES, such as late stent thrombosis. [19] The BASKET trial subgroup analysis showed that patients with large coronary artery lesions had an increased risk of stent thrombosis in the DES group. [3] However, the BASKET-PROVE trial demonstrated that stent thrombosis risk in large coronary intervention did not differ significantly between DES and BMS groups during two years of follow-up. [7] The duration of dual antiplatelet therapy in BASKET trial was 6 months, and which in BASKET-PROVE was 12 months. The different durations of dual antiplatelet therapy used in these two trials might explain the difference in results. [20] During the 9-year follow-up period in our study, only 12 (2.3%) BMS and 9 (1.8%) DES recipients developed definite and probable stent thrombosis (P = 0.5127). In this study, all DES patients received dual antiplatelet therapy for at least 12 months, same as the duration of BASKET-PROVE trial. In this study, no significant increase in the overall rate of stent thrombosis was seen with DES. However, of the 19 DES thrombosis cases, 17 (89.5%) were very late stent thrombosis (Table 7) , that was significantly more frequent in patients with DES after the first year following the procedure. As an observational study showed that the extended use of clopidogrel in patients with DES might be associated with a reduced risk for death and death or MI, [21] our findings may suggest the need for a longer duration of dual antiplatelet therapy in patients receiving DES, especially for first generation DES.
Study limitations
First, although we established a well-balanced cohort of patients receiving BMS and DES matched on the basis of the propensity score, some effect from residual unmeasured confounding may contribute to our findings. Second, because of the lack of angiographic follow-up, we can't assess binary restenosis rates. Third, the second generation DES was not included in this study, and it is necessary to evaluate the efficacy of the newest-generation DES versus BMS in large coronary arteries in further study.
Conclusions
In this large, real-world population, the use of DES in large coronary arteries is associated with significant reductions in the risks of TLR and TVR at 9-year long-term follow-up compared to BMS. There is no significant difference in all-cause mortality, MI, and thrombosis between DES and BMS in patients with large coronary arteries.
